biostudies-literatureUnknownRebecca VWNCI NIH HHSNIH HHSResistance to combination BRAF/MEK inhibitor (BRAFi/MEKi) therapy arises in nearly every patient with <i>BRAF</i>^V600E/K melanoma, despite promising initial responses. Achieving cures in this expanding BRAFi/MEKi-resistant cohort represents one of the greatest challenges to the field; few experience additional durable benefit from immunotherapy and no alternative therapies exist. To better personalize therapy in cancer patients to address therapy relapse, umbrella trials have been initiated whereby genomic sequencing of a panel of potentially actionable targets guide therapy selection for patients; however, the superior efficacy of such approaches remains to be seen. We here test the robustness of the umbrella trial rationale by analyzing relationships between genomic status of bioRxiv : the preprint server for biology2023.01.20.524923https://www.ebi.ac.uk/biostudies/studies/S-EPMC9882271biostudies-literatureDasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.PMC9882271R50 CA211199S10 OD023586U54 CA224070P30 CA010815P01 CA114046K01 CA245124P01 CA025874R01 CA047159R01 CA182890Fingerman DJi HHerlyn MBravo JVillanueva JRebecca VWLiu QBrown GSGopal YNVFane MENathanson KWei MXiao MGodok TKossenkov ADavies MAChen YAlicea GMfalseDasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.Resistance to combination BRAF/MEK inhibitor (BRAFi/MEKi) therapy arises in nearly every patient with <i>BRAF</i>^V600E/K melanoma, despite promising initial responses. Achieving cures in this expanding BRAFi/MEKi-resistant cohort represents one of the greatest challenges to the field; few experience additional durable benefit from immunotherapy and no alternative therapies exist. To better personalize therapy in cancer patients to address therapy relapse, umbrella trials have been initiated whereby genomic sequencing of a panel of potentially actionable targets guide therapy selection for patients; however, the superior efficacy of such approaches remains to be seen. We here test the robustness of the umbrella trial rationale by analyzing relationships between genomic status of 2023-01-01T00:00:00Z2023 Jan2025-04-05T11:27:53.446Z2025-04-05T11:27:53.446ZS-EPMC98822713671181410.1101/2023.01.20.524923